CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 87 enrolled
Drug / intervention
ATI-501 400mg BID (Low dose) +3 moredrug
Likely dose
ATI-501 400mg BID (Low dose)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03594227
NCT03594227Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Aclaris Therapeutics, Inc.·interventional·Posted Jul 20, 2018·Updated Sep 16, 2020

In Brief

A Phase 2 clinical trial evaluating ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), and 2 other interventions for Alopecia. Completed, enrolled 87 participants across 25 sites.

Detailed Summary

This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 20, 2018
Enrollment StartJun 11, 2018
Primary CompletionJun 6, 2019
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.0 years ago

Interventions

ATI-501 400mg BID (Low dose)drug

ATI-501 400mg BID oral low dose for oral administration

ATI-501 600mg BID (Mid dose)drug

ATI-501 600mg BID oral mid dose for oral administration

ATI-501 800mg BID (High dose)drug

ATI-501 800mg BID high dose for oral administration

Placebodrug

Placebo - oral administration